New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
09:19 EDTSNN, AZN, WAG, SHPGShire, AstraZeneca, Smith & Nephew slump amid inversion fears, FT says
Shares of several companies that may be impacted by increased scrutiny of "tax inversion" deals by U.S. lawmakers fell in U.K. trading, including Shire (SHPG), AstraZeneca (AZN), and Smith & Nephew (SNN), reported Financial Times. The slumps come after the U.S. Treasury said it was “reviewing a broad range of authorities for possible administrative action” to limit inversions and after Walgreen (WAG) decided it would not pursue an inversion as part of its deal to acquire the remaining stake in Alliance Boots that it does not already own. Reference Link
News For SHPG;AZN;SNN;WAG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 1, 2015
07:43 EDTAZNExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
April 30, 2015
07:09 EDTSHPGShire reaffirms 2015 EPS growth outlook of mid-single digits
Shire said, "We've made a strong start to 2015, and remain confident in delivering Non GAAP diluted earnings per ADS growth in the mid-single digits in 2015. On a Constant Exchange Rate basis we continue to expect product sales growth in the mid-to-high single digits. When excluding INTUNIV, we anticipate low double digit product sales growth on a CER basis. Based on current exchange rates we anticipate low-to-mid single digit product sales growth in 2015, as we expect growth to be held back three to four percentage points by foreign exchange headwinds which particularly impact ELAPRASE, REPLAGAL and VPRIV sales. We expect to see a lower rate of product sales growth through the remainder of 2015 than we've delivered in the first quarter, principally due to stronger comparatives. Royalties and other revenues are expected to increase by 30-40% in 2015, as we include NPS's royalty streams for the first time. Our Non GAAP gross margin is expected to be in line with 2014."
07:08 EDTSHPGShire reports Q1 adjysted EPS $2.84, consensus $2.61
Subscribe for More Information
07:06 EDTSHPGShire appoints Jeff Poulton as CFO
Subscribe for More Information
April 29, 2015
10:39 EDTAZNCiti analyst says outlook still strong for big pharma
Subscribe for More Information
10:00 EDTSHPGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:18 EDTAZNAstraZeneca says FDA grants priority review for new indication of Brilinta
AstraZeneca announced that the FDA has accepted a supplemental new drug application and granted Priority Review for BRILINTA tablets for patients with a history of heart attack. The sNDA is based on the results of the PEGASUS-TIMI 54 study, a large-scale outcomes trial in more than 21,000 patients that investigated ticagrelor tablets plus low dose aspirin, compared to placebo plus low dose aspirin, for the chronic secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study enrollment. The Prescription Drug User Fee Act goal date will be in the third quarter of 2015. A Priority Review designation is granted to medicines that the FDA determines have the potential to provide significant improvements in the treatment, prevention or diagnosis of a disease. PEGASUS-TIMI 54 is part of AstraZeneca’s PARTHENON program. The PLATO study, involving over 18,000 patients, was the first study in the program and is the basis on which ticagrelor has been approved in over 100 countries and included in 12 major ACS treatment guidelines globally. Further ongoing PARTHENON studies are assessing ticagrelor for the prevention of cardiovascular events in patients with peripheral arterial disease, ischemic stroke or transient ischemic attack, and in patients with diabetes and coronary atherosclerosis. BRILINTA is not approved for secondary prevention of atherothrombotic events in patients with a history of heart attack beyond one year or for the prevention of cardiovascular events in patients with peripheral arterial disease, stroke, diabetes or atherosclerosis.
05:33 EDTSHPGShire initiated with an Outperform at Exane BNP Paribas
Subscribe for More Information
April 27, 2015
08:41 EDTAZNTelegraph discusses potential takeover of GSK by Pfizer
Subscribe for More Information
06:19 EDTAZNPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
06:19 EDTAZNAstraZeneca says smaller M&A deals more realistic, Reuters reports
Subscribe for More Information
06:07 EDTAZNAstraZeneca reiterates outlook for FY15
Subscribe for More Information
06:06 EDTAZNAstraZeneca reports Q1 core EPS $1.08, consensus $1.05
Reports Q1 revenue $6.06B, consensus $5.95B. Reports Q1 Symbicort revenue $845M vs. $928M last year, Pulmicort revenue $286M vs. $263M last year, Crestor revenue $1.17B vs. $1.33B last year, Nexium revenue $644M vs. $930M last year.
05:39 EDTAZNCelgene announces strategic collaboration with AstraZeneca
Subscribe for More Information
05:37 EDTAZNAstraZeneca signs co-development agreement with Innate Pharma
Subscribe for More Information
April 23, 2015
15:01 EDTAZNNotable companies reporting before tomorrow's open
Subscribe for More Information
09:20 EDTSHPGCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 1–10 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The ’501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
08:25 EDTAZNJuno Therapeutics, MedImmune announce immuno-oncology trial collaboration
Subscribe for More Information
April 22, 2015
08:04 EDTAZNBIND Therapeutics presents data on BIND-014, AZD2811 at AACR
Subscribe for More Information
07:07 EDTSHPGEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use